Developing Recombinant Anti-Idiotypic Antibodies for PK/PD and Immunogenicity Assays



February 20, 2017

"For more information, visit Dr Achim Knappik of AbD Serotec describes the use of recombinant anti-idiotypic antibodies as specialized tools in the development of preclinical and clinical research assays for antibody drug development and how they are generated using proprietary HuCAL® recombinant antibody generation technology. Dr Knappik is the main inventor of the HuCAL technology. He defines and illustrates the types of anti-drug antibodies and their applications in determining the levels of therapeutic antibody drugs in serum and the detection of patient immune response to the drug. The HuCAL PLATINUM® antibody library, containing ~45 billion members, is used with a guided selection method to generate high-affinity, anti-idiotypic antibodies (as Fabs) in just eight weeks; these monoclonal anti-idiotypic antibodies can be generated in large quantities with great consistency, and they can be further engineered to allow various assay designs. The presentation concludes with a case study of the development of anti-trastuzumab (Herceptin®) antibodies and highlights a few of the company's anti-idiotypic antibody products. Presenter: Dr Achim Knappik Head of Research and Development at AbD Serotec, a Bio-Rad company AbD Serotec offers both an extensive range of primary and secondary antibodies and reagents as well as custom antibody generation services including anti-idiotypic antibodies. HuCAL® and HuCAL PLATINUM® are registered trademarks of MorphoSys AG. Herceptin® is a registered trademark of Genentech Inc. USA."


Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.